MAMichael H. Albert

Michael H. Albert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michael H. Albert has a total of 791 co-authors. Here are the top co-authors by number of shared publications:

  • Ansgar Schulz

    Department of Pediatrics, University Medical Center, Ulm, Germany

    11 shared publications
  • Fabian Hauck

    Department of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig-Maximilians-Universitat, Munich, Germany; University Children's Hospital Heidelberg-Mannheim Ltd., Ruprecht-Karls-Universitat Heidelberg, Heidelberg, Germany

    10 shared publications
  • Andrew R. Gennery

    Children’s Haematopoietic Stem Cell Transplant Unit, Great North Children’s Hospital, Newcastle upon Tyne Hospital National Health Service Foundation Trust, Newcastle upon Tyne, United Kingdom

    9 shared publications
  • Christoph Klein

    Pediatric Hematology/Oncology, Dr von Hauner University Children's Hospital, Munich, Germany

    9 shared publications
  • Arjan C. Lankester

    Willem-Alexander Children’s Hospital, Leiden University Medical Center, Leiden, the Netherlands

    8 shared publications
  • Bénédicte Neven

    33Department of Immunology and Stem Cell Transplantation, Hôpital Necker Enfants Malades, Paris, France

    8 shared publications

Latest Publications

  • Open Access

    TTC7A deficiency: A retrospective international study on treatment and outcomes from the Inborn Errors Working Party of EBMT

    by Giulia Prunotto, Marie Parreillet, Bénédicte Neven, Despina Moshous, Genevieve de Saint Basile, Caroline Lindemans, Timothy Ronan Leahy, Elie Haddad, Herbert Pichler, Joao Farela Neves, et al.

    Prunotto et al. describe clinical presentation, immunological status, treatment, and long-term outcomes of a large cohort of pediatric and adult patients affected by an extremely complex and rare immunodeficiency known as TTC7A deficiency for which no clear therapeutic pathway is currently available.

  • Open Access

    ADA2 genotype and enzyme activity may predict vasculitic or hematologic DADA2 phenotype

    by Philipp Peters, Johanna Schepp, Michael H. Albert, Horst von Bernuth, Norbert Blank, Jürgen Brunner, Gregor Dückers, Lisa Ehlers, Susan Farmand, Dirk Föll, et al.

    Deficiency of adenosine deaminase 2 (DADA2) is an autoinflammatory disease with diverse phenotypes. We describe the genetics, phenotypes, and treatment of n = 48 DADA2 patients from Germany, Austria, and Switzerland. We report a high incidence of hematological (83%) and immunological features (85%), a comparatively low anti-tumor necrosis factor full-response rate (58%), and a high decision probability (21%) for hematopoietic cell transplantation (HCT). We establish a correlation between genetic variant ADA2 activity and patient ADA2 activity. Remarkably, lower patient ADA2 activity is predictive of neutropenia and shows a trend toward HCT decision, whereas higher patient ADA2 activity is predictive of vasculitis symptoms. Genetic variants with low residual ADA2 activity are significantly more common among patients receiving HCT. Our study corroborates previous observations connecting ADA2 activity and clinical phenotype, which up to now have been mainly based on in vitro data.

  • Open Access

    Updated EBMT/ESID inborn errors working party guidelines for haematopoietic stem cell transplantation for inborn errors of immunity and metabolism

    by M. H. Albert, A. C. Lankester, R. Wynn, A. R. Gennery, M. Hoenig, A. Kreins, E. C. Morris, M. Slatter, M. E. Bernardo, B. Neven


  • Open Access

    Outcome of second conditioned allogeneic stem cell transplant in children with non-SCID inborn errors of immunity

    by Zohreh Nademi, Su Han Lum, Patrick Gilbert, Tiarlan Sirait, Musa Karakukcu, Franco Locatelli, Ansgar S Schulz, Jolanta Gozdzik, Aydan Ikinciogullari, Krzysztof Kalwak, et al.

    Graft failure (GF) after allogeneic hematopoietic stem cell transplant (HSCT) is a life-threatening complication. The Inborn Errors Working Party conducted a retrospective study to examine the outcome of a second HSCT for children with nonsevere combined immunodeficiency (SCID) inborn errors of immunity (IEI); 159 children from 37 centers who received a second transplant between 2009 and 2020 were included in this analysis. The median interval between first and second HSCT was 6.9 months (0.7-155.2 months). The 5-year overall survival (OS) and event-free survival (EFS) rates were 78% and 69%, respectively. The second HSCT for primary GF had a significantly lower OS (69%, 55%-83% vs secondary GF, 81%, 73%-89%; P = .044) and EFS (52%, 37%-68% vs secondary GF, 75%, 67%-84%; P< .001). Improved EFS was observed in patients who received myeloablative conditioning/reduced-toxicity conditioning (74%, 66%-81%) compared with nonmyeloablative conditioning (50%, 29%-71%; P = .003), but this association was not observed in OS. Upon multivariable analysis, cord blood was the only independent negative predictor for EFS (hazard ratio, 4.9, 1.3-18.7; P = .020). The 1-year cumulative incidence (CIN) of all GF after the second HSCT was 13% (95% confidence interval, 8%-19%). The day-100 CINs of grade 2 and grade 3 to 4 acute graft-versus-host disease were 19% (13%-25%) and 8% (4%-13%), respectively. Whole-blood chimerism >90% was reported in 84.3% at last follow-up. We report, to our knowledge, the first international experience with the largest cohort of second conditioned HSCT in non-SCID IEI to date. This study provides valuable insights into the clinical outcomes following second transplant, identifying key predictors of survival.


  • Open Access

    Hematopoietic stem cell transplantation for purine nucleoside phosphorylase deficiency: an EBMT-IEWP retrospective study

    by Uli S. Herrmann, Matthias Felber, Austen Worth, Sule Haskologlu, Figen Dogu, Victor A. Lewis, Brigitte Strahm, Andreas Groll, Andrew R. Gennery, Fabian Hauck, et al.

    Purine nucleoside phosphorylase (PNP) deficiency causes inadequate purine metabolite detoxification, which leads to combined immunodeficiency and variable neurologic symptoms. Hematopoietic stem cell transplantation (HSCT) cures the immunodeficiency, but large studies on the long-term outcomes are lacking. In a retrospective study of the European Society for Blood and Marrow Transplantation, we investigated 46 patients with PNP deficiency from 21 centers. We analyzed the presenting clinical signs and outcomes after HSCT. Cognition (0-3), hearing (0-3), interaction (0-4), movement (0-4), and occupation (0-3) (CHIMO) were scored at the last follow-up (FU) visit (no impairment, 17; mild, 15-16; moderate, 12-14; and severe impairment, 50%-100%)/low-level donor chimerism (11%-50%) was observed in 85%/15% of patients, respectively, leading to resolution of T lymphopenia. The median overall CHIMO score was 14 (6-17), while the median scores for each component were 3 (0-3), 3 (1-3), 4 (1-4), 3 (1-4), and 2 (0-3), respectively. Patients who underwent HSCT before 24 months after the initial presentation demonstrated superior OS (P = .049). Neurological symptoms that occurred before 11 months of age were associated with reduced OS (P = .027). While the overall results were satisfactory, earlier diagnosis could further improve outcomes.


  • Open Access

    Allogeneic hematopoietic stem cell transplantation for STAT3 hyper-IgE syndrome: a worldwide study

    by Christo Tsilifis, Johannes Raedler, Joanna Renke, Michael Medinger, Alexandra Laberko, Ásgeir Haraldsson, Niraj Patel, Peter Ciznar, Melanie Wong, Steven J. Keogh, et al.

    Signal transduction and activator of transcription 3 hyperimmunoglobulin E syndrome (STAT3-HIES) is a multisystem disorder causing recurrent skin and respiratory infection with bronchiectasis, pneumatoceles, and aspergillosis; lymphoma; and extraimmune manifestations including fractures and vasculopathy. Published data on immune and extraimmune hematopoietic stem cell transplant (HSCT) outcomes focus on case reports or small cohorts. We conducted an international multicenter retrospective study of HSCT in STAT3-HIES. Primary end points were overall survival (OS) and event-free survival (EFS; events were death, graft failure, chronic graft-versus-host disease [GVHD]). We identified 41 patients over a 28-year period. HSCT indication was infection (93%) or lymphoma (7%). Median age at HSCT was 14 years (range, 4-45). Most patients had pre-HSCT respiratory disease (93%), including parenchymal lung disease (68%), and prior suspected/confirmed pulmonary fungal infection (32%). Patients received peripheral blood stem cells (51%) or marrow (49%) from HLA 10/10–matched unrelated donors (44%), matched family donors (44%), mismatched family donors (10%), or 1 9/10–mismatched unrelated donor (2%). Conditioning regimens were predominantly treosulfan-based (59%; with thiotepa, 34%); other patients received busulfan-based (24%) or melphalan-based (17%) regimens. Median follow-up for surviving patients was 5 years (0.8-28). The 5-year OS was 93%, and 5-year EFS 90%. Cumulative incidence of grade 2 to 4 acute GVHD was 22%. Median whole blood donor chimerism at latest follow-up was 100%. Eighty-seven percent of patients have reduced or no bacterial or fungal respiratory infection. After HSCT, 20% developed new skeletal fractures. This worldwide study expanded data on HSCT for STAT3-HIES to 41 patients; despite significant pre-HSCT pulmonary morbidity, OS was high, and patients have improved skin and respiratory disease though the impact on extraimmune manifestations appears limited.


  • Top Cited Papers
    Open Access

    Improved outcome of HSCT in STAT1 gain-of-function disease following JAK inhibition bridging

    by Emilie Pauline Buddingh, Mary Slatter, Juan Carlos Aldave Becerra, Laura Alonso Garcia, Erik von Asmuth, Safa Baris, Oscar de la Calle-Martín, Alice Y. Chan, Su-Wan Bianca Chan, Shanmuganathan Chandrakasan, et al.

    Germline gain-of-function (GOF) mutations in signal transducer and activator of transcription 1 (STAT1) are associated with infections, including chronic mucocutaneous candidiasis and autoimmunity. Morbidity is high, and disease manifestations can be life-threatening. Curative allogeneic hematopoietic stem cell transplantation (HSCT) historically has had poor outcomes. We identified 36 patients with STAT1 GOF disease, receiving 40 HSCT procedures in 2010–2023, in a combined effort of the EBMT-IEWP and the PIDTC. Median age at first transplant was 11 years (range 1–33). Indications for HSCT were combined immunodeficiency, severe and/or refractory infections, and autoimmunity. Acute GvHD occurred in 22/40 HSCT procedures; 5 patients suffered from grade III/IV acute GvHD. One patient had chronic GvHD. Overall survival was 72.2%, and event-free survival was 55.6%, markedly improved from an earlier report on HSCT for STAT1 GOF disease. Patients with an HCT-CI score of 1 or higher had worse outcome. Pre-treatment with Janus kinase (JAK) inhibitors was associated with better event-free survival.


  • Open Access

    Inborn errors of immunity: Manifestation, treatment, and outcome—an ESID registry 1994–2024 report on 30,628 patients

    by Gerhard Kindle, Mickaël Alligon, Michael H. Albert, Matthew Buckland, J. David Edgar, Benjamin Gathmann, Sujal Ghosh, Antonios Gkantaras, Alexandra Nieters, Claudio Pignata, et al.

    The European Society for Immunodeficiencies patient registry (ESID-R), established in 1994, is one of the world’s largest databases on inborn errors of immunity (IEI). IEI are genetic disorders predisposing patients to infections, autoimmunity, inflammation, allergies, and malignancies. Treatments include antimicrobial therapy, immunoglobulin replacement, immune modulation, stem cell transplantation, and gene therapy. Data from 194 centers in 33 countries capture clinical manifestations and treatments from birth onward, with annually expected updates. This report reviews the ESID-R’s structure, data content, and impact. The registry includes 30,628 patient datasets (aged 0–97.9 years; median follow-up: 7.2 years; total 825,568.2 patient-years), with 13,550 cases in 15 sub-studies. It has produced 84 peer-reviewed publications (mean citation rate: 95). Findings include real-world observations of IEI diagnoses, genetic causes, clinical manifestations, treatments, and survival trends. The ESID-R fosters global collaboration, advancing IEI research and patient care. This report highlights the key role of the multinational ESID-R, led by an independent medical society, in evidence-based discovery.


  • How I treat Wiskott-Aldrich syndrome

    by Tanja C. Vallée, Michael H. Albert, Sung-Yun Pai

    Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder, characterized by thrombocytopenia, eczema, recurrent infections, autoimmunity, and malignancy. Here, we discuss current conservative and definitive approaches to treating WAS, based on recently published evidence. Disease severity in WAS is highly variable. Recent studies confirm that the probability of disease progression depends on the type of genetic variant, supporting early diagnosis and tailored treatment strategies. Milder cases, historically termed X-linked thrombocytopenia (XLT), received supportive care, whereas severe cases were referred for standard allogeneic hematopoietic cell transplantation (HCT) or gene therapy (GT) in clinical trials. Advances in HCT and GT, together with recent knowledge that even patients with XLT are at risk for severe immune complications, suggest that most young patients with WAS should be offered a potentially curative approach at diagnosis. Older patients with a small subset of milder variants may be treated conservatively unless they develop life-threatening autoimmune or malignant complications; regular monitoring and proactive management are critical to preventing irreversible complications. We recommend discontinuing the term XLT as it implies a mild and uncomplicated disease, which is not the norm, and instead tailor treatment for all patients with WAS to their individual genetic profile, disease severity, and clinical course.


  • HLA-haploidentical stem cell transplantation for chronic granulomatous disease: an EBMT-IEWP retrospective study

    by Quentin Riller, Mathias Hauri, Su Han Lum, Jeroen Knippenberg, Tiarlan Sirait, Alexandra Laberko, Khalid Halahleh, Hasan Hashem, Musa Karakukcu, Henrik Sengeloev, et al.

    Chronic granulomatous disease (CGD) is an inborn error of immunity characterized by defective NAD phosphate oxidase function, leading to impaired microbial killing, recurrent infections, and granulomatous inflammation. Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative treatment for CGD, particularly effective when a fully HLA-matched donor is available. However, the place of HLA-haploidentical HSCT remains less established. This retrospective multicenter study analyzed outcomes of 64 patients with CGD (53 males; 46 with X-linked CGD) who underwent a first HSCT with HLA-haploidentical family donors, with either in vitro T-cell receptor (TCR)αβ/CD19 depletion or in vivo depletion using posttransplant cyclophosphamide (PTCY). The mean age at transplant was 5.8 years (range, 0-33). Patients exhibited a high disease burden before HSCT, with 45% experiencing infections in the 6 months before HSCT and 67% exhibiting inflammation. Outcomes in the entire cohort showed a 3-year overall survival, event-free survival (EFS), and grade 3 to 4 graft-versus-host disease (GVHD)–free EFS of 75.9%, 70.2%, and 56.1%, respectively, and were not affected by the type of depletion or age. The cumulative incidence (CI) of primary graft failure (PGF) was 20.6%. The CI of grade 2 to 4 acute GVHD was higher in the PTCY group (P = .04), whereas the CI of grade 3 to 4 GVHD was not. These results indicate that HLA-haploidentical HSCT is a feasible transplant option for patients with CGD lacking HLA-matched donors. Further refinement of transplant protocols is necessary to mitigate graft failure and acute GVHD, ultimately improving access and outcomes for this life-saving therapy.